Barclays PLC Glycomimetics Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Glycomimetics Inc stock. As of the latest transaction made, Barclays PLC holds 76 shares of GLYC stock, worth $18. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 76 -0.0%

Holding current value

$18

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$1.13 - $2.54 $85 - $193	-76 Reduced 50.0%	76 $0
Q3 2023 Nov 07, 2023	BUY	$1.29 - $1.73 $98 - $131	76 Added 100.0%	152 $0
Q4 2022 Feb 13, 2023	BUY	$0.57 - $3.03 $43 - $230	76 New	76 $0
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $6,939 - $10,312	-4,819 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$1.8 - $2.39 $25,252 - $33,529	-14,029 Reduced 74.43%	4,819 $11,000
Q2 2021 Aug 13, 2021	SELL	$2.16 - $3.18 $26,291 - $38,706	-12,172 Reduced 39.24%	18,848 $44,000
Q1 2021 May 13, 2021	BUY	$2.89 - $4.22 $54,956 - $80,247	19,016 Added 158.41%	31,020 $93,000
Q4 2020 Feb 11, 2021	SELL	$2.69 - $4.24 $21,958 - $34,611	-8,163 Reduced 40.48%	12,004 $45,000
Q3 2020 Nov 12, 2020	SELL	$3.07 - $5.0 $16,237 - $26,445	-5,289 Reduced 20.78%	20,167 $62,000
Q2 2020 Aug 12, 2020	BUY	$2.06 - $3.76 $17,184 - $31,365	8,342 Added 48.74%	25,456 $96,000
Q1 2020 May 13, 2020	SELL	$1.83 - $5.41 $73,836 - $218,282	-40,348 Reduced 70.22%	17,114 $39,000
Q4 2019 Feb 10, 2020	BUY	$4.03 - $6.5 $69,219 - $111,644	17,176 Added 42.64%	57,462 $304,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $16,654 - $76,431	5,948 Added 17.32%	40,286 $174,000
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $215,317 - $266,506	-20,313 Reduced 37.17%	34,338 $410,000
Q1 2019 May 15, 2019	BUY	$9.96 - $13.44 $420,939 - $568,014	42,263 Added 341.16%	54,651 $681,000
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $120,926 - $210,014	-14,277 Reduced 53.54%	12,388 $118,000
Q3 2018 Nov 14, 2018	SELL	$13.7 - $17.12 $6,754 - $8,440	-493 Reduced 1.82%	26,665 $384,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $394,614 - $517,611	-26,973 Reduced 49.83%	27,158 $438,000
Q1 2018 May 15, 2018	SELL	$16.06 - $25.35 $111,087 - $175,345	-6,917 Reduced 11.33%	54,131 $878,000
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $308,773 - $505,906	29,379 Added 92.77%	61,048 $1.03 Million
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $321,123 - $470,284	31,669	31,669 $443,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $12.6M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account